The findings, from the SPACE study, paved the way for FDA approval of AJOVY for pediatric patients aged 6-17 years weighing 45 kilograms
The investigational therapy uses SteadyTeq, a proprietary copolymer technology from Medincell designed to release olanzapine steadily over time
No post-injection Delirium/Sedation Syndrome (PDSS) observed through 56 weeks
Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development
Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month
This approval showcases Teva’s proven strengths in complex generic formulations development and device engineering
Subscribe To Our Newsletter & Stay Updated
